Jan. 29, 2007 - Empi, a global market leader in non-invasive, non-systemic pain management and physical rehabilitation for more than 30 years, today announced that the FDA has granted clearance to market the Empi Select TENS (Transcutaneous Electrical Nerve Stimulation) device.
The Select device is designed specifically for the relief of chronic, arthritic, and post-surgical pain. The portable device can be used at home or on-the-go, and integrates site specific, preset treatment programs that make it convenient and easy-to-use. This feature ensures that the patient receives the appropriate electrotherapy treatment, specific to their condition and treatment site.
The Select device also includes a patented SMP waveform that delivers maximum pain relief through the use of both endorphin release and gate control pathways. "Empi's primary focus is to offer healthcare providers non-invasive, non-systemic solutions for managing pain, usually as a complement to standard pharmacotherapies," said Peter Baird, Group President - Therapeutic Devices of Encore Medical Corporation, parent company of Empi.
The Select device represents the cornerstone of Empi's brand revitalization efforts and is the first new electrotherapy device to be developed by Empi following its 2006 merger with Compex Technologies, Inc., which operated under the name Rehabilicare. The jointly developed product draws on the best of the engineering and legacy devices of both predecessor companies.
The Select device will be available from Family Practice, Pain Management, Orthopedic and other physicians in mid-February, 2007.